Latanoprost Viatris (Latanoprost)

• Latanoprost is used in the management of ocular conditions that require reduction of intra‑ocular pressure.
• Primary open‑angle glaucoma: lowers intra‑ocular pressure, helping to preserve visual field and delay disease progression.
• Ocular hypertension: reduces elevated eye pressure to prevent conversion to glaucoma.
• Elevated intra‑ocular pressure (any cause): provides consistent pressure reduction to protect optic nerve health.

• Latanoprost binds to prostaglandin F (FP) receptors in the ciliary muscle, promoting remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor. This enhanced outflow lowers intra‑ocular pressure, thereby reducing stress on the optic nerve and slowing glaucomatous damage.

Latanoprost may cause ocular and systemic reactions after topical administration.

Common Side Effects

• Conjunctival hyperemia (eye redness)
• Increased eyelash length and thickness
• Iris pigmentation darkening
• Eye irritation or foreign‑body sensation
• Blurred vision
• Mild pruritus of the eyelid

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angio‑edema, anaphylaxis)
• Ocular inflammation such as uveitis or keratitis
• Paradoxical increase in intra‑ocular pressure
• Corneal edema or endothelial dysfunction
• Vision loss or sudden visual disturbances
• Systemic hypersensitivity (e.g., rash, fever)

• Before initiating therapy, clinicians should evaluate patient history and monitor ocular response.
• Assess baseline intra‑ocular pressure: confirm need for pressure‑lowering therapy.
• Monitor iris color changes: document pigmentation at each visit.
• Evaluate for history of uveitis or ocular infection: avoid use during active inflammation.
• Avoid concurrent use with other prostaglandin analog eye drops: risk of additive effects.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at ambient temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost may interact with other ophthalmic agents, altering efficacy or safety.

Major Interactions (Avoid)

• Concomitant prostaglandin analog eye drops: additive pressure‑lowering effect may cause hypotony.
• Topical ocular steroids: may diminish Latanoprost's IOP‑lowering action.
• Anticholinergic eye drops: potential for reduced drug absorption.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation.
• Systemic carbonic anhydrase inhibitors: additive IOP reduction, monitor pressure.
• Antihistamine eye drops: possible decreased efficacy, observe pressure response.